Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
De novo device clearances fall out of fashion
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Luck, strategy and FDA device approvals
Experience and high staff levels help companies negotiate FDA approval – but luck plays a part.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.